NO328071B1 - 2,4-pyrimidinaminforbindelser, farmasoytisk sammensetning, in-vito fremgangsmater ved anvendelse av forbindelsene, mellomprodukter samt fremgangsmater for fremstilling av mellom- og sluttprodukter - Google Patents

2,4-pyrimidinaminforbindelser, farmasoytisk sammensetning, in-vito fremgangsmater ved anvendelse av forbindelsene, mellomprodukter samt fremgangsmater for fremstilling av mellom- og sluttprodukter Download PDF

Info

Publication number: NO328071B1
Authority: NO; Norway
Prior art keywords: group; fluoro; chloro; pyrimidinamine; compound according
Prior art date: 2002-02-01

Application number

NO20043632A

Other languages

English (en)

Norwegian (no)

Other versions

NO20043632L (no

Inventor

Rajinder Singh

Ankush Argade

Donald G Payan

Susan Molineaux

Sacha J Holland

Jeffrey Clough

Holger Keim

Somasekhar Bhamidipati

Catherine Sylvain

Hui Li

Alexander B Rossi

Original Assignee

Rigel Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-01

Filing date

2004-08-31

Publication date

2009-11-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32996332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328071(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-31 Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc

2004-10-26 Publication of NO20043632L publication Critical patent/NO20043632L/no

2009-11-23 Publication of NO328071B1 publication Critical patent/NO328071B1/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20043632A 2002-02-01 2004-08-31 2,4-pyrimidinaminforbindelser, farmasoytisk sammensetning, in-vito fremgangsmater ved anvendelse av forbindelsene, mellomprodukter samt fremgangsmater for fremstilling av mellom- og sluttprodukter NO328071B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US35333302P	2002-02-01	2002-02-01
US35326702P	2002-02-01	2002-02-01
US39967302P	2002-07-29	2002-07-29
US43427702P	2002-12-17	2002-12-17
PCT/US2003/003022 WO2003063794A2 (en)	2002-02-01	2003-01-31	2,4-pyrimidinediamine compounds and their uses

Publications (2)

Publication Number	Publication Date
NO20043632L NO20043632L (no)	2004-10-26
NO328071B1 true NO328071B1 (no)	2009-11-23

Family

ID=32996332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20043632A NO328071B1 (no)	2002-02-01	2004-08-31	2,4-pyrimidinaminforbindelser, farmasoytisk sammensetning, in-vito fremgangsmater ved anvendelse av forbindelsene, mellomprodukter samt fremgangsmater for fremstilling av mellom- og sluttprodukter

Country Status (24)

Country	Link
US (41)	US7557210B2 (pt)
EP (2)	EP2281563B1 (pt)
JP (2)	JP4658477B2 (pt)
KR (1)	KR101037856B1 (pt)
CN (2)	CN102174024B (pt)
AT (1)	ATE524184T1 (pt)
AU (2)	AU2003208931C1 (pt)
BR (1)	BRPI0307355C1 (pt)
CA (1)	CA2474277C (pt)
CY (1)	CY1112516T1 (pt)
DK (2)	DK2281563T3 (pt)
ES (2)	ES2440283T3 (pt)
HR (1)	HRP20040684B1 (pt)
IL (1)	IL221381A (pt)
MX (2)	MXPA04007386A (pt)
NO (1)	NO328071B1 (pt)
NZ (1)	NZ534361A (pt)
PL (1)	PL214988B1 (pt)
PT (2)	PT1471915E (pt)
RS (2)	RS54105B1 (pt)
SG (1)	SG167664A1 (pt)
SI (2)	SI1471915T1 (pt)
TW (1)	TWI329105B (pt)
WO (1)	WO2003063794A2 (pt)

Families Citing this family (394)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002312933B2 (en) *	2001-05-29	2007-12-06	Schering Ag	CDK inhibiting pyrimidines, production thereof and their use as medicaments
CA2451128A1 (en)	2001-06-26	2003-01-09	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of tnf-alpha expression
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
DK1438053T3 (da) *	2001-10-17	2008-12-08	Boehringer Ingelheim Pharma	Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
WO2003066601A1 (en) *	2002-02-08	2003-08-14	Smithkline Beecham Corporation	Pyrimidine compounds
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
CN1688553A (zh) *	2002-06-17	2005-10-26	史密丝克莱恩比彻姆公司	化学方法
SI1534286T1 (sl) *	2002-07-29	2010-04-30	Rigel Pharmaceuticals Inc	Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
BR0313059B8 (pt)	2002-07-29	2021-07-27	Rigel Pharmaceuticals	composto, e, composição farmacêutica
CN102702111B (zh) *	2002-08-09	2014-12-17	詹森药业有限公司	制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
KR20050084027A (ko) *	2002-11-28	2005-08-26	쉐링 악티엔게젤샤프트	Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
UA80767C2 (en) *	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
EA013248B1 (ru)	2002-12-20	2010-04-30	Пфайзер Продактс Инк.	Производные пиримидина для лечения патологического роста клеток
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004022633D1 (de) *	2003-01-30	2009-10-01	Boehringer Ingelheim Pharma	2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
CL2004000303A1 (es) *	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
DE602004021472D1 (en) *	2003-02-20	2009-07-23	Smithkline Beecham Corp	Pyrimiidinverbindungen
GB0305929D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
US7504396B2 (en)	2003-06-24	2009-03-17	Amgen Inc.	Substituted heterocyclic compounds and methods of use
DK1658302T3 (da)	2003-07-25	2010-11-22	Idenix Pharmaceuticals Inc	Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
CN102358738A (zh)	2003-07-30	2012-02-22	里格尔药品股份有限公司	2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
EP1648875A1 (en) *	2003-07-30	2006-04-26	Cyclacel Limited	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
TWI378923B (en) *	2003-08-15	2012-12-11	Novartis Ag	Pyrimidine derivatives
GB0321710D0 (en)	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
WO2005049573A1 (en)	2003-11-05	2005-06-02	F. Hoffmann-La Roche Ag	Phenyl derivatives as ppar agonists
BRPI0416519A (pt) *	2003-11-14	2007-03-06	Ashland Licensing & Intellectu	composição oligomérica lìquida, produto polimerizado curado, método para fabricar e para usar uma composição oligomérica lìquida, e, substrato
WO2005095382A1 (ja) *	2004-03-30	2005-10-13	Kyowa Hakko Kogyo Co., Ltd.	抗腫瘍剤
MXPA06011658A (es)	2004-05-14	2006-12-14	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
WO2005111016A1 (en)	2004-05-14	2005-11-24	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en)	2004-05-14	2005-11-24	Pfizer Products Inc.	Pyrimidines derivatives for the treatment of abnormal cell growth
US7754714B2 (en) *	2004-05-18	2010-07-13	Rigel Pharmaceuticals, Inc.	Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) *	2004-05-19	2005-11-23	Boehringer Ingelheim International GmbH	2-Arylaminopyrimidine als PLK Inhibitoren
WO2006004776A1 (en) *	2004-06-29	2006-01-12	Rigel Pharmaceuticals, Inc.	4-pyrimidineamine compounds and their uses as anti-proliferative agents
US20060051406A1 (en) *	2004-07-23	2006-03-09	Manjeet Parmar	Formulation of insoluble small molecule therapeutics in lipid-based carriers
GB0419160D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
WO2006028833A1 (en) *	2004-09-01	2006-03-16	Rigel Pharmaceuticals, Inc.	Synthesis of 2,4-pyrimidinediamine compounds
JP2008512429A (ja) *	2004-09-10	2008-04-24	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
EP1796679A1 (en) *	2004-09-10	2007-06-20	Altana Pharma AG	Ciclesonide and syk inhibitor combination and methods of use thereof
CA2579143A1 (en)	2004-09-13	2006-03-23	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
CA2581623A1 (en)	2004-09-23	2006-03-30	Reddy Us Therapeutics, Inc.	Novel pyridine compounds, process for their preparation and compositions containing them
EP1794135A1 (en) *	2004-09-27	2007-06-13	Amgen Inc.	Substituted heterocyclic compounds and methods of use
CA2577467C (en)	2004-09-30	2013-05-28	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 5-heterocyclyl pyrimidines
RU2410379C2 (ru)	2004-09-30	2011-01-27	Тиботек Фармасьютикалз Лтд.	5-замещенные пиримидины, ингибирующие вич
WO2006050476A2 (en)	2004-11-03	2006-05-11	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as ion channel modulators and methods of use
GB2420559B (en) *	2004-11-15	2008-08-06	Rigel Pharmaceuticals Inc	Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
JP5095409B2 (ja) *	2004-11-24	2012-12-12	ライジェルファーマシューティカルズ，インコーポレイテッド	スピロ２，４−ピリミジンジアミン化合物およびその使用
MY169441A (en) *	2004-12-08	2019-04-11	Janssen Pharmaceutica Nv	2,4, (4,6) pyrimidine derivatives
JP2008524246A (ja)	2004-12-16	2008-07-10	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
US7555655B2 (en) *	2004-12-22	2009-06-30	5th Fleet, L.L.C.	Apparatus, system, and method for generating and authenticating a computer password
JP4801096B2 (ja) *	2005-01-19	2011-10-26	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
US20060270694A1 (en) *	2005-05-03	2006-11-30	Rigel Pharmaceuticals, Inc.	JAK kinase inhibitors and their uses
WO2006122319A2 (en)	2005-05-11	2006-11-16	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US20070203161A1 (en) *	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP1904457B1 (en)	2005-06-08	2017-09-06	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CA2607901C (en) *	2005-06-13	2016-08-16	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
DE602005000514T2 (de) *	2005-06-17	2007-10-25	Magneti Marelli Powertrain S.P.A.	Brennstoffeinspritzventil
WO2007028445A1 (en) *	2005-07-15	2007-03-15	Glaxo Group Limited	6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
PE20070362A1 (es) *	2005-07-15	2007-04-23	Glaxo Group Ltd	COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
EP1746096A1 (en) *	2005-07-15	2007-01-24	4Sc Ag	2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
JP4850912B2 (ja)	2005-09-01	2012-01-11	エフ．ホフマン−ラロシュアーゲー	Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
WO2007042571A1 (en)	2005-10-14	2007-04-19	Neurosearch A/S	Novel pyrimidine-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
US8604042B2 (en) *	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) *	2005-11-01	2009-05-05	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) *	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP2009518443A (ja)	2005-12-06	2009-05-07	リゲルファーマシューティカルズインコーポレーティッド	脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
US7713987B2 (en) *	2005-12-06	2010-05-11	Rigel Pharmaceuticals, Inc.	Pyrimidine-2,4-diamines and their uses
JP5400388B2 (ja)	2005-12-15	2014-01-29	ライジェルファーマシューティカルズ，インコーポレイテッド	キナーゼインヒビターおよびその利用
JP2007186507A (ja) *	2005-12-15	2007-07-26	Nippon Nohyaku Co Ltd	フタルアミド誘導体及び農園芸用殺虫剤並びにその使用方法
RS20080272A (sr) *	2005-12-21	2009-07-15	Pfizer Products Inc.,	Derivati pirimidina za tretman neprirodnog rasta ćelija
WO2007085540A1 (en) *	2006-01-27	2007-08-02	Glaxo Group Limited	1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
JP4653842B2 (ja) *	2006-02-17	2011-03-16	ライジェルファーマシューティカルズ，インコーポレイテッド	自己免疫疾患を治療または予防するための２，４−ピリミジンジアミン化合物
JP2009528295A (ja) *	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
EP2004632B1 (en)	2006-03-30	2014-03-12	Janssen R&D Ireland	Hiv inhibiting 5-amido substituted pyrimidines
CA2657260A1 (en) *	2006-07-21	2008-01-24	Novartis Ag	2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US8445437B2 (en) *	2006-07-27	2013-05-21	The Brigham And Women's Hospital, Inc.	Treatment and prevention of cardiovascular disease using mast cell stabilizers
AR063946A1 (es) *	2006-09-11	2009-03-04	Cgi Pharmaceuticals Inc	Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
ATE497496T1 (de) *	2006-10-19	2011-02-15	Rigel Pharmaceuticals Inc	2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
ES2555803T3 (es)	2006-10-23	2016-01-08	Cephalon, Inc.	Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
WO2008105968A1 (en) *	2006-11-03	2008-09-04	Smithkline Beecham Corporation	Novel seh inhibitors and their use
ES2380551T3 (es)	2006-11-21	2012-05-16	Rigel Pharmaceuticals, Inc.	Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
BRPI0722383A2 (pt)	2006-12-08	2012-06-05	Irm Llc	compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
CA2673965A1 (en)	2006-12-28	2008-07-10	Taisho Pharmaceutical Co., Ltd.	Pyrazolopyrimidine compound
US9006243B2 (en)	2006-12-29	2015-04-14	Janssen R&D Ireland	HIV inhibiting 6-substituted pyrimidines
CN106045965A (zh)	2006-12-29	2016-10-26	爱尔兰詹森科学公司	抑制hiv的5,6‑取代的嘧啶类化合物
US7947698B2 (en)	2007-03-23	2011-05-24	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
US7834024B2 (en)	2007-03-26	2010-11-16	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
EP2154967B9 (en)	2007-04-16	2014-07-23	Hutchison Medipharma Enterprises Limited	Pyrimidine derivatives
AP2009005010A0 (en)	2007-04-18	2009-10-31	Pfizer Prod Inc	Sulfonyl amide derivatives for the treatment of abnormal cell growth
CN101903357A (zh)	2007-07-17	2010-12-01	里格尔药品股份有限公司	作为pkc抑制剂的环状胺取代的嘧啶二胺
CN101861314B (zh)	2007-09-05	2013-07-24	里格尔制药公司	N4-[(2,2-二氟-4h-苯并[1,4]*嗪-3-酮)-6-基]-5-氟-n2-[3-(甲基氨基羰基亚甲基氧基)苯基]-2,4-嘧啶二胺的1-羟基-2-萘甲酸盐
JP5460600B2 (ja)	2007-09-28	2014-04-02	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	肥満症治療における肥満細胞安定化薬
US8008483B2 (en) *	2007-10-11	2011-08-30	GlaxoSmithKline, LLC	sEH inhibitors and their use
US20100210655A1 (en) *	2007-10-11	2010-08-19	Yun Ding	NOVEL sEH INHIBITORS AND THEIR USE
CN101896065B (zh) *	2007-10-11	2013-12-18	葛兰素史密斯克莱有限责任公司	新的sEH抑制剂及其用途
BRPI0820389A2 (pt) *	2007-11-07	2015-05-19	Rigel Pharmaceuticals Inc	Formulação granulada usando um agente sequestrador de água
WO2009071535A1 (en) *	2007-12-03	2009-06-11	Boehringer Ingelheim International Gmbh	Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP2011506333A (ja) *	2007-12-06	2011-03-03	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規ｓＥＨ阻害剤およびその使用
US20100311776A1 (en) *	2008-01-30	2010-12-09	Smithkline Beecham Corporation	Novel sEH Inhibitors and their Use
JP2011510996A (ja) *	2008-01-30	2011-04-07	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規ｓＥＨ阻害剤およびその使用
HUE030912T2 (en)	2008-02-15	2017-06-28	Rigel Pharmaceuticals Inc	Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
MX2010011463A (es) *	2008-04-16	2011-06-03	Portola Pharm Inc	2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
JP5705720B2 (ja) *	2008-04-16	2015-04-22	ポートラファーマシューティカルズ，インコーポレイテッド	Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
KR20100132550A (ko) *	2008-04-16	2010-12-17	포톨라 파마슈티컬스, 인코포레이티드	ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
JP2011518219A (ja)	2008-04-22	2011-06-23	ポートラファーマシューティカルズ，インコーポレイテッド	タンパク質キナーゼの阻害剤
US7829574B2 (en)	2008-05-09	2010-11-09	Hutchison Medipharma Enterprises Limited	Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
WO2009153180A1 (en)	2008-06-16	2009-12-23	F. Hoffmann-La Roche Ag	Heteroaromatic monoamides as orexinin receptor antagonists
NZ603525A (en)	2008-06-27	2015-02-27	Celgene Avilomics Res Inc	Pyrimidine based compound and uses thereof
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2013202496B2 (en) *	2008-06-27	2016-08-04	Celgene Car Llc	Heteroaryl compounds and uses thereof
US8426430B2 (en)	2008-06-30	2013-04-23	Hutchison Medipharma Enterprises Limited	Quinazoline derivatives
TW201008933A (en)	2008-08-29	2010-03-01	Hutchison Medipharma Entpr Ltd	Pyrimidine compounds
CA2736258C (en)	2008-09-23	2016-11-29	Rigel Pharmaceuticals, Inc.	Tricyclic carbamate jak inhibitors
TW201016676A (en) *	2008-10-03	2010-05-01	Astrazeneca Ab	Heterocyclic derivatives and methods of use thereof
JP5815411B2 (ja)	2008-12-30	2015-11-17	ライジェルファーマシューティカルズ，インコーポレイテッド	ピリミジンジアミンキナーゼ阻害剤
CA2749195C (en) *	2009-01-15	2017-03-07	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
ES2635504T3 (es)	2009-01-21	2017-10-04	Rigel Pharmaceuticals, Inc.	Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas
PL2389372T3 (pl)	2009-01-23	2016-02-29	Rigel Pharmaceuticals Inc	Kompozycje i sposoby hamowania szlaku JAK
JP2012517448A (ja) *	2009-02-11	2012-08-02	リアクションバイオロジーコープ．	選択的キナーゼ阻害剤
JP5918693B2 (ja)	2009-05-05	2016-05-18	ダナファーバーキャンサーインスティテュートインコーポレイテッド	Ｅｇｆｒ阻害剤及び疾患の治療方法
US8367689B2 (en)	2009-05-06	2013-02-05	Portola Pharmaceuticals, Inc.	Inhibitors of JAK
WO2010143733A1 (en)	2009-06-09	2010-12-16	Takeda Pharmaceutical Company Limited	Novel fused cyclic compound and use thereof
UA108077C2 (xx)	2009-07-02	2015-03-25		Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
CA2768368A1 (en)	2009-07-17	2011-01-20	Rigel Pharmaceuticals, Inc.	Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
CA2768543C (en) *	2009-07-28	2017-06-20	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
JP2013508396A (ja) *	2009-10-23	2013-03-07	グラクソウェルカムマニュファクチュアリングピーティーイーリミテッド	組成物および方法
ES2524127T3 (es) *	2009-11-20	2014-12-04	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos
US20110130415A1 (en)	2009-12-01	2011-06-02	Rajinder Singh	Protein kinase c inhibitors and uses thereof
EP2512246B1 (en)	2009-12-17	2015-09-30	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
WO2011075517A1 (en)	2009-12-17	2011-06-23	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
DK2516434T3 (en)	2009-12-23	2015-08-31	Takeda Pharmaceutical	FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS
AT509266B1 (de) *	2009-12-28	2014-07-15	Univ Wien Tech	Substituierte pyridine und pyrimidine
US8367315B2 (en) *	2010-03-05	2013-02-05	Adan Rios	Inactivation of reverse transcriptases by azido-diarylpyrimidines
AU2011240773C1 (en)	2010-04-12	2015-08-27	Supernus Pharmaceuticals Inc.	Methods for producing viloxazine salts and novel polymorphs thereof
CA2792278C (en)	2010-04-13	2019-05-14	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
BR112012029647A2 (pt)	2010-05-21	2016-08-02	Chemilia Ab	novos derivados de pirimidinas
EP2395001A1 (en)	2010-05-21	2011-12-14	Chemilia AB	Novel pyrimidine derivatives
US8354420B2 (en)	2010-06-04	2013-01-15	Genentech, Inc.	Aminopyrimidine derivatives as LRRK2 inhibitors
JP6035238B2 (ja)	2010-07-21	2016-11-30	ライジェルファーマシューティカルズ，インコーポレイテッド	プロテインキナーゼｃ阻害剤およびその使用
KR101937495B1 (ko)	2010-07-28	2019-01-10	리겔 파마슈티칼스, 인크.	Ｊａｋ 경로의 억제를 위한 조성물 및 방법
CN105566229A (zh)	2010-08-10	2016-05-11	西建阿维拉米斯研究公司	Btk抑制剂的苯磺酸盐及其用途和制备方法
EP2635557A2 (en)	2010-11-01	2013-09-11	Portola Pharmaceuticals, Inc.	Nicotinamides as jak kinase modulators
US20130317029A1 (en)	2010-11-01	2013-11-28	Portola Pharmaceuticals, Inc.	Oxypyrimidines as syk modulators
US9238629B2 (en)	2010-11-01	2016-01-19	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
SG10201508958WA (en)	2010-11-01	2015-11-27	Celgene Avilomics Res Inc	Heterocyclic Compounds And Uses Thereof
CA2816219C (en)	2010-11-01	2019-10-29	Portola Pharmaceuticals, Inc.	Nicotinamides as syk modulators
WO2012060847A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
EP2637502B1 (en)	2010-11-10	2018-01-10	Celgene CAR LLC	Mutant-selective egfr inhibitors and uses thereof
SI2638031T1 (en)	2010-11-10	2018-02-28	Genentech, Inc.	Pyrazole aminopyrimidine derivatives as LRRK2 modulators
WO2012097207A2 (en) *	2011-01-13	2012-07-19	The Johns Hopkins University	Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
JP5886411B2 (ja)	2011-03-24	2016-03-16	ノビガ・リサーチ・エービーＮｏｖｉｇａＲｅｓｅａｒｃｈＡＢ	新規のピリミジン誘導体
EP2502924A1 (en)	2011-03-24	2012-09-26	Chemilia AB	Novel pyrimidine derivatives
US9249124B2 (en)	2011-03-30	2016-02-02	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase inhibitors and methods of making and using thereof
HRP20240097T1 (hr)	2011-04-22	2024-03-29	Signal Pharmaceuticals, Llc	Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima
AU2016244228B2 (en) *	2011-04-22	2019-02-21	Signal Pharmaceuticals, Llc	Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
CA2834062A1 (en)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Pyridyl aminopyridines as syk inhibitors
AU2012253885A1 (en)	2011-05-10	2013-10-31	Merck Sharp & Dohme Corp.	Aminopyrimidines as Syk inhibitors
US9145391B2 (en)	2011-05-10	2015-09-29	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines as Syk inhibitors
WO2012167423A1 (en)	2011-06-08	2012-12-13	Hutchison Medipharma Limited	Substituted pyridopyrazines as novel syk inhibitors
WO2012177714A1 (en)	2011-06-22	2012-12-27	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives
KR102024120B1 (ko)	2011-07-28	2019-09-23	리겔 파마슈티칼스, 인크.	신규한 (트리메톡시페닐아미노)피리미디닐 제형
AU2012300567B2 (en) *	2011-09-02	2016-03-10	Purdue Pharma L.P.	Pyrimidines as sodium channel blockers
JP2014530177A (ja) *	2011-09-16	2014-11-17	フオベア・フアルマシユテイカル	アニリン誘導体、それらの調製およびそれらの治療適用
WO2013052393A1 (en)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2763974B1 (en)	2011-10-05	2016-09-14	Merck Sharp & Dohme Corp.	Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763976B1 (en)	2011-10-05	2016-05-18	Merck Sharp & Dohme Corp.	2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US20130102596A1 (en)	2011-10-21	2013-04-25	Rigel Pharmaceuticals, Inc.	Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
JP2014532658A (ja)	2011-10-28	2014-12-08	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ブルトン型チロシンキナーゼ疾患または障害を治療する方法
SG11201402570QA (en)	2011-11-23	2014-06-27	Portola Pharm Inc	Pyrazine kinase inhibitors
CN104169275B (zh) *	2012-01-13	2017-06-09	百时美施贵宝公司	用作激酶抑制剂的三唑取代的吡啶化合物
CA2866857C (en)	2012-03-15	2021-03-09	Celgene Avilomics Research, Inc.	Salts of an epidermal growth factor receptor kinase inhibitor
JP6317319B2 (ja)	2012-03-15	2018-04-25	セルジーンシーエーアールエルエルシー	上皮成長因子受容体キナーゼ阻害剤の固体形態
NZ631340A (en)	2012-03-23	2016-11-25	Univ Queensland	Immunomodulatory agent and uses therefor
WO2013152198A1 (en)	2012-04-04	2013-10-10	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
CN104470515B (zh)	2012-05-03	2016-12-07	圣路易斯药学院	用于增加神经营养肽的组合物和方法
WO2013173506A2 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
WO2013192128A1 (en)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Imidazolyl analogs as syk inhibitors
EP2863914B1 (en)	2012-06-20	2018-10-03	Merck Sharp & Dohme Corp.	Pyrazolyl derivatives as syk inhibitors
US9416111B2 (en)	2012-06-22	2016-08-16	Merck Sharp & Dohme Corp.	Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
EP2863916B1 (en)	2012-06-22	2018-07-18	Merck Sharp & Dohme Corp.	Substituted pyridine spleen tyrosine kinase (syk) inhibitors
KR101446742B1 (ko)	2012-08-10	2014-10-01	한국화학연구원	Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US9353066B2 (en)	2012-08-20	2016-05-31	Merck Sharp & Dohme Corp.	Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
EP2711364A1 (en)	2012-09-21	2014-03-26	Chemilia AB	4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en)	2012-09-21	2014-03-26	Chemilia AB	4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US9586931B2 (en)	2012-09-28	2017-03-07	Merck Sharp & Dohme Corp.	Triazolyl derivatives as Syk inhibitors
US9676756B2 (en)	2012-10-08	2017-06-13	Portola Pharmaceuticals, Inc.	Substituted pyrimidinyl kinase inhibitors
CA2892677A1 (en)	2012-12-04	2014-06-12	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
US9624210B2 (en)	2012-12-12	2017-04-18	Merck Sharp & Dohme Corp.	Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2935226A4 (en)	2012-12-21	2016-11-02	Celgene Avilomics Res Inc	HETEROARYL COMPOUNDS AND USES THEREOF
US9598405B2 (en)	2012-12-21	2017-03-21	Merck Sharp & Dohme Corp.	Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
JP2016506930A (ja)	2013-01-25	2016-03-07	ライジェルファーマシューティカルズ，インコーポレイテッド	炎症性腸疾患を処置するための化合物および方法
US9561228B2 (en)	2013-02-08	2017-02-07	Celgene Avilomics Research, Inc.	ERK inhibitors and uses thereof
JP6433974B2 (ja)	2013-03-14	2018-12-05	トレロファーマシューティカルズ，インコーポレイテッド	Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
CA2904610A1 (en)	2013-03-14	2014-09-25	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
WO2014152716A1 (en) *	2013-03-15	2014-09-25	President And Fellows Of Harvard College	Substituted heterocyclic compounds for treating or preventing viral infections
EP2988749B1 (en)	2013-04-26	2019-08-14	Merck Sharp & Dohme Corp.	Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en)	2013-04-26	2014-10-30	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3013823B1 (en) *	2013-06-24	2017-11-01	Merck Patent GmbH	Imidazole compounds as modulators of fshr and uses thereof
EP3030241A4 (en)	2013-08-06	2019-06-19	H. Lee Moffitt Cancer Center And Research Institute, Inc.	INHIBITORS OF ACK1 / TNK2.TYROSINE KINASE
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9783531B2 (en)	2013-12-20	2017-10-10	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
WO2015095445A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en)	2013-12-20	2021-10-27	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CN106535889A (zh)	2014-02-10	2017-03-22	帕塔拉制药有限责任公司	用于治疗肺疾病的肥大细胞稳定剂
CA2938994A1 (en)	2014-02-10	2015-08-13	Patara Pharma, LLC	Inhalable formulations of sodium cromolyn with improved bioavailability
EP4019518A1 (en)	2014-02-28	2022-06-29	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
WO2015138273A1 (en)	2014-03-13	2015-09-17	Merck Sharp & Dohme Corp.	2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
JP6517319B2 (ja)	2014-03-28	2019-05-22	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されたヘテロアリール化合物および使用方法
CN117164657A (zh)	2014-08-12	2023-12-05	莫纳什大学	定向淋巴的前药
US10005760B2 (en)	2014-08-13	2018-06-26	Celgene Car Llc	Forms and compositions of an ERK inhibitor
EP3206691B1 (en)	2014-10-14	2018-09-19	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
KR102754019B1 (ko)	2014-10-29	2025-01-14	바이시클러드 리미티드	Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
EP3233808B1 (en)	2014-12-16	2021-07-14	Signal Pharmaceuticals, LLC	Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
WO2016100310A1 (en)	2014-12-16	2016-06-23	Signal Pharmaceuticals, Llc	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
CA2975260C (en)	2015-01-29	2024-05-21	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ES2930585T3 (es)	2015-02-27	2022-12-19	Nimbus Lakshmi Inc	Inhibidores de TYK2 y usos de los mismos
WO2016196385A1 (en)	2015-05-29	2016-12-08	Portola Pharmaceuticals, Inc.	Cerdulatinib for the treatment of b-cell malignancies
WO2017004134A1 (en)	2015-06-29	2017-01-05	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
KR20180041119A (ko)	2015-07-09	2018-04-23	메르크 파텐트 게엠베하	Btk 억제제로서 피리미딘 유도체 및 이의 용도
ES2994877T3 (en)	2015-07-24	2025-02-03	Celgene Corp	Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EP3331522A1 (en)	2015-08-07	2018-06-13	Patara Pharma LLC	Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en)	2015-08-07	2019-04-23	Respivant Sciences Gmbh	Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CN108025013A (zh)	2015-08-12	2018-05-11	博尔托拉制药公司	用于治疗骨髓瘤的赛度替尼
JP6802263B2 (ja)	2015-09-02	2020-12-16	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
EP3347340A4 (en)	2015-09-08	2019-01-23	Monash University	LYMPHENLEITUNGSPRODRUGS
US10683308B2 (en)	2015-09-11	2020-06-16	Navitor Pharmaceuticals, Inc.	Rapamycin analogs and uses thereof
EP3347097B1 (en)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
AU2016342027B2 (en)	2015-10-23	2021-05-13	Navitor Pharmaceuticals, Inc.	Modulators of Sestrin-GATOR2 interaction and uses thereof
US10045981B2 (en)	2015-11-24	2018-08-14	Jakpharm, Llc	Selective kinase inhibitors
WO2017096303A2 (en)	2015-12-04	2017-06-08	Portola Pharmaceuticals, Inc.	Cerdulatinib for treating hematological cancers
EP3389664A4 (en)	2015-12-14	2020-01-08	Raze Therapeutics Inc.	MTHFD2 CAFFEINE INHIBITORS AND USE THEREOF
CN105646371B (zh) *	2016-01-19	2019-10-01	浙江大学	含异羟肟酸片段的2,4-二芳胺基嘧啶类衍生物及制备和应用
PT3426243T (pt)	2016-03-09	2021-08-19	Raze Therapeutics Inc	Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
EP3426244B1 (en)	2016-03-09	2023-06-07	Raze Therapeutics, Inc.	3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2017156527A1 (en) *	2016-03-11	2017-09-14	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
WO2017177230A1 (en)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Methods for treating cancer
JP7054529B2 (ja)	2016-06-21	2022-04-14	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
CA3027500A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
EP3506893A4 (en)	2016-08-31	2020-01-22	Respivant Sciences GmbH	CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
WO2018053190A1 (en)	2016-09-14	2018-03-22	Gilead Sciences, Inc.	Syk inhibitors
TW201822764A (zh)	2016-09-14	2018-07-01	美商基利科學股份有限公司	Syk抑制劑
AU2017339366A1 (en)	2016-10-07	2019-04-11	Respivant Sciences Gmbh	Cromolyn compositions for treatment of pulmonary fibrosis
CN115448916B (zh)	2016-10-14	2026-04-28	武田药品工业株式会社	Tyk2抑制剂及其用途
JP7082120B2 (ja)	2016-10-21	2022-06-07	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
WO2018089499A1 (en)	2016-11-08	2018-05-17	Navitor Pharmaceuticals, Inc.	PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
AU2017368050A1 (en)	2016-11-29	2019-06-20	Puretech Lyt, Inc.	Exosomes for delivery of therapeutic agents
US11091451B2 (en)	2016-12-05	2021-08-17	Raze Therapeutics, Inc.	SHMT inhibitors and uses thereof
US11730819B2 (en)	2016-12-23	2023-08-22	Bicycletx Limited	Peptide derivatives having novel linkage structures
WO2018127699A1 (en)	2017-01-06	2018-07-12	Bicyclerd Limited	Compounds for treating cancer
CN108341835B (zh) *	2017-01-22	2021-01-15	正大天晴药业集团股份有限公司	用作酪氨酸激酶抑制剂的含硼化合物
TWI868528B (zh)	2017-03-08	2025-01-01	日商武田藥品工業股份有限公司	Ｔｙｋ２抑制劑之生產方法
EP3375784A1 (en)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Aza-dihydro-acridone derivatives
EP3375778A1 (en)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Aryl-piperidine derivatives
EP3680241A1 (en)	2017-03-20	2020-07-15	Forma Therapeutics, Inc.	Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
WO2018191146A1 (en)	2017-04-10	2018-10-18	Navitor Pharmaceuticals, Inc.	Heteroaryl rheb inhibitors and uses thereof
WO2018195471A1 (en)	2017-04-21	2018-10-25	Gilead Sciences, Inc.	Syk inhibitors in combination with hypomethylating agents
TWI776886B (zh)	2017-04-26	2022-09-11	美商奈維特製藥公司	Sestrin-gator2交互作用之調節劑及其用途
US10857196B2 (en)	2017-04-27	2020-12-08	Bicycletx Limited	Bicyclic peptide ligands and uses thereof
CN111032678A (zh)	2017-06-26	2020-04-17	拜西克尔德有限公司	具有可检测部分的双环肽配体和其用途
AU2018294054B2 (en) *	2017-06-30	2022-05-26	Beijing Tide Pharmaceutical Co., Ltd.	Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
WO2019023468A1 (en)	2017-07-28	2019-01-31	Nimbus Lakshmi, Inc.	TYK2 INHIBITORS AND USES THEREOF
EP3659307A4 (en) *	2017-07-28	2021-09-22	Yale University	ANTI-CANCER PRODUCTS AND METHOD FOR MANUFACTURING AND USING THEREOF
ES2926195T3 (es)	2017-08-04	2022-10-24	Bicycletx Ltd	Ligandos peptídicos bicíclicos específicos de CD137
WO2019034866A1 (en)	2017-08-14	2019-02-21	Bicyclerd Limited	BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
EP3668550A1 (en)	2017-08-14	2020-06-24	Bicyclerd Limited	Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019046491A1 (en)	2017-08-29	2019-03-07	Ariya Therapeutics, Inc.	LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11883497B2 (en)	2017-08-29	2024-01-30	Puretech Lyt, Inc.	Lymphatic system-directing lipid prodrugs
WO2019060693A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	CRBN LIGANDS AND USES THEREOF
JP7366031B2 (ja)	2017-09-22	2023-10-20	カイメラセラピューティクス，インコーポレイテッド	タンパク質分解剤およびそれらの使用
US10052326B1 (en)	2017-10-12	2018-08-21	King Saud University	Antihepatotoxic agents
CA3079292A1 (en)	2017-10-19	2019-04-25	Bayer Animal Health Gmbh	Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019090198A1 (en)	2017-11-06	2019-05-09	Bristol-Myers Squibb Company	Isofuranone compounds useful as hpk1 inhibitors
WO2019099311A1 (en)	2017-11-19	2019-05-23	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
US11304954B2 (en)	2017-12-19	2022-04-19	Puretech Lyt, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en)	2017-12-19	2023-03-21	Puretech Lyt, Inc.	Lipid prodrugs of rapamycin and its analogs and uses thereof
TWI825046B (zh)	2017-12-19	2023-12-11	英商拜西可泰克斯有限公司	Epha2特用之雙環胜肽配位基
GB201721265D0 (en)	2017-12-19	2018-01-31	Bicyclerd Ltd	Bicyclic peptide ligands specific for EphA2
WO2019126378A1 (en)	2017-12-19	2019-06-27	Ariya Therapeutics, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
US11512080B2 (en)	2018-01-12	2022-11-29	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
EP3737666A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
EP4616913A3 (en)	2018-01-29	2025-12-10	Merck Patent GmbH	Gcn2 inhibitors and uses thereof
JP7377207B2 (ja)	2018-01-29	2023-11-09	メルクパテントゲーエムベーハー	Ｇｃｎ２阻害剤およびその使用
AU2019224659A1 (en)	2018-02-23	2020-10-15	Bicycletx Limited	Multimeric bicyclic peptide ligands
EP3759086A1 (en)	2018-02-27	2021-01-06	Artax Biopharma Inc.	Chromene derivatives as inhibitors of tcr-nck interaction
BR112020020246A8 (pt)	2018-04-05	2022-10-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de cinase axl e uso dos mesmos
HUE067936T2 (hu)	2018-04-24	2024-11-28	Merck Patent Gmbh	Proliferáció-gátló vegyületek és alkalmazásuk
WO2019209757A1 (en)	2018-04-24	2019-10-31	Vertex Pharmaceuticals Incorporated	Pteridinone compounds and uses thereof
EP3788035B1 (en)	2018-05-04	2024-08-07	Alexion Pharmaceuticals, Inc.	Solid forms of cerdulatinib
IL314362A (en)	2018-06-15	2024-09-01	Janssen Pharmaceutica Nv	Rapamycin analogs and their uses
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en)	2018-06-22	2018-08-08	Bicyclerd Ltd	Peptide ligands for binding to EphA2
US10487057B1 (en) *	2018-07-05	2019-11-26	Landos Biopharma, Inc.	NLRX1 ligands
EP3817822A4 (en)	2018-07-06	2022-07-27	Kymera Therapeutics, Inc.	PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Tricyclic crbn ligands and uses thereof
WO2020023910A1 (en)	2018-07-26	2020-01-30	Tolero Pharmaceuticals, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
EP3846793B1 (en)	2018-09-07	2024-01-24	PIC Therapeutics, Inc.	Eif4e inhibitors and uses thereof
US10675274B2 (en)	2018-09-19	2020-06-09	Forma Therapeutics, Inc.	Activating pyruvate kinase R
WO2020061255A1 (en)	2018-09-19	2020-03-26	Forma Therapeutics, Inc.	Activating pyruvate kinase r
CA3115088A1 (en)	2018-10-15	2020-04-23	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
US10919937B2 (en)	2018-10-23	2021-02-16	Bicycletx Limited	Bicyclic peptide ligands and uses thereof
JP7644002B2 (ja)	2018-10-24	2025-03-11	ナビターファーマシューティカルズ，インコーポレイテッド	多形化合物およびその使用
JP7623943B2 (ja)	2018-11-30	2025-01-29	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
CN113271938A (zh)	2018-11-30	2021-08-17	林伯士拉克许米公司	Tyk2抑制剂和其用途
GB201820288D0 (en)	2018-12-13	2019-01-30	Bicycle Tx Ltd	Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en)	2018-12-13	2019-01-30	Bicyclerd Ltd	Bicyclic peptide ligands specific for psma
GB201820295D0 (en)	2018-12-13	2019-01-30	Bicyclerd Ltd	Bicyclic peptide ligands specific for MT1-MMP
EP3670659A1 (en)	2018-12-20	2020-06-24	Abivax	Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
US12551567B2 (en)	2018-12-21	2026-02-17	Bicyclerd Limited	Bicyclic peptide ligands specific for PD-L1
CN113474045A (zh)	2018-12-21	2021-10-01	拜斯科技术开发有限公司	Pd-l1特异性的双环肽配体
AU2020212001A1 (en)	2019-01-23	2021-07-22	Takeda Pharmaceutical Company Limited	TYK2 inhibitors and uses thereof
WO2020165600A1 (en)	2019-02-14	2020-08-20	Bicycletx Limited	Bicyclic peptide ligand sting conjugates and uses thereof
EP3942045A1 (en)	2019-03-21	2022-01-26	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022528887A (ja)	2019-04-02	2022-06-16	バイスクルテクス・リミテッド	バイシクルトキシンコンジュゲートおよびその使用
US11485750B1 (en)	2019-04-05	2022-11-01	Kymera Therapeutics, Inc.	STAT degraders and uses thereof
WO2020243423A1 (en)	2019-05-31	2020-12-03	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2020251972A1 (en)	2019-06-10	2020-12-17	Kymera Therapeutics, Inc.	Smarca degraders and uses thereof
WO2020251971A1 (en)	2019-06-10	2020-12-17	Kymera Therapeutics, Inc.	Smarca degraders and uses thereof
BR112021026517A2 (pt)	2019-06-28	2022-05-10	Kymera Therapeutics Inc	Degradadores de irak e usos dos mesmos
JP2022539208A (ja)	2019-07-03	2022-09-07	スミトモファーマオンコロジー，インコーポレイテッド	チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
WO2021011868A1 (en)	2019-07-17	2021-01-21	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
TWI860386B (zh)	2019-07-30	2024-11-01	英商拜西可泰克斯有限公司	異質雙環肽複合物
BR112022001418A2 (pt)	2019-08-08	2022-06-07	Rigel Pharmaceuticals Inc	Compostos e método para tratar a síndrome de liberação de citocinas
CN115038688A (zh)	2019-09-11	2022-09-09	文森雷生物科学股份有限公司	Usp30抑制剂及其用途
PH12022550605A1 (en)	2019-09-13	2023-09-25	Nimbus Saturn Inc	Hpk1 antagonists and uses thereof
HUE072832T2 (hu)	2019-09-19	2025-12-28	Novo Nordisk Healthcare Ag	Piruvát kináz R-t (PKR) aktiváló készítmények
EP4051259A4 (en)	2019-11-01	2023-11-22	Navitor Pharmaceuticals, Inc.	METHOD OF TREATMENT USING A MMOC1 MODULATOR
EP4054579A1 (en)	2019-11-08	2022-09-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021094296A1 (en)	2019-11-12	2021-05-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of mast cell stabilizer for the treatment of heart failure with preserved ejection fraction
BR112022010754A2 (pt)	2019-12-05	2022-08-23	Anakuria Therapeutics Inc	Análogos de rapamicina e usos dos mesmos
EP4072591A4 (en)	2019-12-10	2024-06-05	Kymera Therapeutics, Inc.	IRAQ DEGRADER AND USES THEREOF
JP2023509366A (ja)	2019-12-17	2023-03-08	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
WO2021127283A2 (en)	2019-12-17	2021-06-24	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
CN115297931A (zh)	2019-12-23	2022-11-04	凯麦拉医疗公司	Smarca降解剂和其用途
US12569485B2 (en)	2019-12-23	2026-03-10	Kymera Therapeutics, Inc.	SMARCA inhibitors and uses thereof
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
JP2023513016A (ja) *	2020-01-30	2023-03-30	スミトモファーマオンコロジー，インコーポレイテッド	Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
AU2021217172A1 (en)	2020-02-05	2022-09-22	Monash University	Lipid prodrugs of neurosteroids
MX2022010944A (es)	2020-03-03	2022-11-09	Pic Therapeutics Inc	Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
AU2021234316A1 (en)	2020-03-12	2022-10-13	Rigel Pharmaceuticals, Inc.	Method for treatment of COVID-19-associated conditions
IL296451B2 (en)	2020-03-19	2026-05-01	Kymera Therapeutics Inc	MDM2 joints and their uses
WO2021247897A1 (en)	2020-06-03	2021-12-09	Kymera Therapeutics, Inc.	Deuterated irak degraders and uses thereof
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
CA3189761A1 (en)	2020-08-03	2022-02-10	Gemma Mudd	Peptide-based linkers
KR20230074721A (ko)	2020-08-17	2023-05-31	바이사이클티엑스 리미티드	Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
JP2023546996A (ja)	2020-10-23	2023-11-08	ニンバスクロソー，インコーポレイテッド	Ｃｔｐｓ１阻害剤およびその使用
IL303376A (en)	2020-12-02	2023-08-01	Ikena Oncology Inc	Tead inhibitors and uses thereof
WO2022120353A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
EP4259144A4 (en)	2020-12-09	2025-08-20	Kymera Therapeutics Inc	SMARCA DEGRADING AGENTS AND THEIR USES
WO2022147465A1 (en)	2020-12-30	2022-07-07	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
CN112920124B (zh)	2021-01-29	2024-03-01	安徽医科大学	一种嘧啶-2,4-二胺类化合物及其制备方法与应用
KR20230153387A (ko)	2021-02-02	2023-11-06	리미널 바이오사이언시스 리미티드	Gpr84 길항제 및 이의 용도
JP2024506858A (ja)	2021-02-02	2024-02-15	リミナル・バイオサイエンシーズ・リミテッド	Ｇｐｒ８４アンタゴニストおよびその使用
WO2022174253A1 (en)	2021-02-12	2022-08-18	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
CN116867494A (zh)	2021-02-15	2023-10-10	凯麦拉医疗公司	Irak4降解剂和其用途
TW202245788A (zh)	2021-02-15	2022-12-01	美商凱麥拉醫療公司	Irak4降解劑及其用途
CN117295737A (zh)	2021-03-05	2023-12-26	林伯士萨顿公司	Hpk1拮抗剂和其用途
US12128035B2 (en)	2021-03-19	2024-10-29	Novo Nordisk Health Care Ag	Activating pyruvate kinase R
WO2022213062A1 (en)	2021-03-29	2022-10-06	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
EP4319756A4 (en)	2021-04-09	2025-02-26	Nimbus Clio, Inc.	CBL-B MODULATORS AND USES THEREOF
WO2022221866A1 (en)	2021-04-16	2022-10-20	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
AU2022271290A1 (en)	2021-05-07	2023-11-23	Kymera Therapeutics, Inc.	Cdk2 degraders and uses thereof
TW202315621A (zh)	2021-08-25	2023-04-16	美商皮克醫療公司	Ｅｉｆ４ｅ抑制劑及其用途
JP2024532276A (ja)	2021-08-25	2024-09-05	ピクセラピューティクス，インコーポレイテッド	ｅＩＦ４Ｅ阻害剤及びその使用
EP4422635A4 (en)	2021-10-29	2025-11-26	Kymera Therapeutics Inc	IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
JP2025503448A (ja)	2021-12-16	2025-02-04	リンクファーマシューティカルズシーオー．エルティーディー．	Ｔｙｋ２阻害剤および組成物ならびにその方法
WO2023108536A1 (en) *	2021-12-16	2023-06-22	Lynk Pharmaceuticals Co. Ltd.	Tyk2 inhibitors and compositions and methods thereof
WO2023114984A1 (en)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
IL314437A (en)	2022-01-31	2024-09-01	Kymera Therapeutics Inc	IRAK joints and their uses
US11478464B1 (en)	2022-02-06	2022-10-25	King Faisal University	Method for treating inflammation
WO2023173057A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023173053A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023211889A1 (en)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Polymorphic compounds and uses thereof
KR102939283B1 (ko) *	2022-05-03	2026-03-13	한국화학연구원	5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20230357125A1 (en) *	2022-05-06	2023-11-09	AMPAC Fine Chemicals	Process for Catalytic Reduction of Nitro Compounds to Amines
KR20250040894A (ko)	2022-05-25	2025-03-25	이케나 온콜로지, 인코포레이티드	Mek 억제제 및 이의 용도
JP2025527248A (ja)	2022-08-02	2025-08-20	リミナル・バイオサイエンシーズ・リミテッド	置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
JP2025527247A (ja)	2022-08-02	2025-08-20	リミナル・バイオサイエンシーズ・リミテッド	アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
JP2025527250A (ja)	2022-08-02	2025-08-20	リミナル・バイオサイエンシーズ・リミテッド	ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
WO2024042361A1 (en) *	2022-08-24	2024-02-29	Sudo Biosciences Limited	Tyk2 inhibitors and uses thereof
TW202430148A (zh)	2022-11-22	2024-08-01	美商皮克醫療公司	ｅＩＦ４Ｅ抑制劑及其用途
CN116003331A (zh) *	2022-12-31	2023-04-25	浙江工业大学	一种2，4-二芳氨基嘧啶衍生物及其应用
US20240374555A1 (en) *	2023-04-10	2024-11-14	Magi's Lab Srl	Mast Cell Stabilizer with Sodium Cromoglycate-based Inhibitor for Preventing Lipedema Progression
EP4615455A2 (en)	2023-06-23	2025-09-17	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
AU2024344754A1 (en)	2023-09-21	2026-04-02	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors for use in the treatment of inflammatory bowel disease

Family Cites Families (313)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US192301A (en) *		1877-06-19		Improvement in lemon-squeezers
US80858A (en) *		1868-08-11		Ensmore
US38243A (en) *		1863-04-21		Improvement in flasks for founders
US113398A (en) *		1871-04-04		Improvement in towel-brackets and sponge-holders
US3159547A (en)	1963-06-28	1964-12-01	Abbott Lab	Method of lowering blood pressure with 4-(2-amino-4-pyrimidylamino)-benzene-sulfonamide
US3320256A (en)	1965-04-09	1967-05-16	Hoffmann La Roche	Fluorinated imidazoo[1, 2-c]pyrimidines and pyrimido[1, 2-c]pyrimidines
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5845466A (ja)	1981-09-10	1983-03-16	松下電器産業株式会社	空気調和機
JPS59122899U (ja)	1983-02-08	1984-08-18	松下電器産業株式会社	アイロン
US4921475A (en)	1983-08-18	1990-05-01	Drug Delivery Systems Inc.	Transdermal drug patch with microtubes
US5087240A (en)	1983-08-18	1992-02-11	Drug Delivery Systems Inc.	Transdermal drug patch with conductive fibers
JPS6036884U (ja)	1983-08-18	1985-03-14	三洋電機株式会社	ドラム式洗濯機
GR80171B (en)	1983-08-29	1985-01-02	Ciba Geigy Ag	N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use
HU192875B (en)	1984-10-05	1987-07-28	Richter Gedeon Vegyeszet	Process for preparing 2-pyridinethiol derivatives
DE3666587D1 (en)	1985-08-02	1989-11-30	Leo Pharm Prod Ltd	Novel vitamin d analogues
US4738851A (en)	1985-09-27	1988-04-19	University Of Iowa Research Foundation, Inc.	Controlled release ophthalmic gel formulation
DE3618353A1 (de)	1986-05-31	1987-12-03	Hoechst Ag	Schaedlingsbekaempfungsmittel auf der basis von aminopyrimidin-derivaten sowie neue aminopyrimidin-verbindungen
JPS638387A (ja)	1986-06-27	1988-01-14	Yoshitomi Pharmaceut Ind Ltd	セフエム化合物
JPH0696592B2 (ja) *	1986-06-30	1994-11-30	株式会社クラレ	１７β−ヒドロキシ−１７α−（３−ヒドロキシプロピル）アンドロスタ−４，６−ジエン−３−オンの製造方法
US5163899A (en)	1987-03-20	1992-11-17	Drug Delivery Systems Inc.	Transdermal drug delivery system
DE3868287D1 (de)	1987-04-02	1992-03-19	Ciba Geigy Ag	Reaktivfarbstoffe, deren herstellung und verwendung.
US5312325A (en)	1987-05-28	1994-05-17	Drug Delivery Systems Inc	Pulsating transdermal drug delivery system
SU1499883A1 (ru)	1987-11-24	1991-10-23	Научно-исследовательский институт фармакологии АМН СССР	Дихлоргидрат 2,4-бис-(п-трет-бутиланилино)-5-окси-6-метилпиримидина, обладающий анальгетической и противовоспалительной активностью
GB8804164D0 (en)	1988-02-23	1988-03-23	Tucker J M	Bandage for administering physiologically active compound
EP0412110B1 (en)	1988-04-21	1993-07-07	Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab)	Novel vitamin d analogues
US4882150A (en)	1988-06-03	1989-11-21	Kaufman Herbert E	Drug delivery system
US5008110A (en)	1988-11-10	1991-04-16	The Procter & Gamble Company	Storage-stable transdermal patch
US5088977A (en)	1988-12-21	1992-02-18	Drug Delivery Systems Inc.	Electrical transdermal drug applicator with counteractor and method of drug delivery
HU206337B (en)	1988-12-29	1992-10-28	Mitsui Petrochemical Ind	Process for producing pyrimidine derivatives and pharmaceutical compositions
IE63502B1 (en)	1989-04-21	1995-05-03	Zeneca Ltd	Aminopyrimidine derivatives useful for treating cardiovascular disorders
US4983608A (en)	1989-09-05	1991-01-08	Hoechst-Roussell Pharmaceuticals, Inc.	N-substituted-4-pyrimidinamines and pyrimidinediamines
US5179204A (en)	1989-09-05	1993-01-12	Hoechst-Roussel Pharmaceuticals Incorporated	N-substituted-4-pyrimidinamines and pyrimidinediamines
US5521222A (en)	1989-09-28	1996-05-28	Alcon Laboratories, Inc.	Topical ophthalmic pharmaceutical vehicles
JPH03127790A (ja) *	1989-10-11	1991-05-30	Morishita Pharmaceut Co Ltd	Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
TW224941B (pt)	1989-11-08	1994-06-11	Yamanouchi Pharma Co Ltd
ATE107176T1 (de)	1989-12-04	1994-07-15	Searle & Co	System zur transdermalen albuterol applikation.
US5532228A (en)	1990-02-06	1996-07-02	Schering Aktiengesellschaft	Side-chain homologous vitamin D derivatives, process for their production, pharmaceutical preparations containing these derivatives and their use as pharmaceutical agents
DE4011682A1 (de)	1990-04-06	1991-10-10	Schering Ag	24-oxa-derivate in der vitamin d-reihe
JPH03127790U (pt)	1990-04-06	1991-12-24
GB9012592D0 (en) *	1990-06-06	1990-07-25	Smithkline Beecham Intercredit	Compounds
US5077033A (en)	1990-08-07	1991-12-31	Mediventures Inc.	Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE4029650A1 (de) *	1990-09-19	1992-03-26	Hoechst Ag	2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
JPH04178385A (ja)	1990-11-09	1992-06-25	Yamanouchi Pharmaceut Co Ltd	ジケトピリドピラジン誘導体
DK0495421T3 (da)	1991-01-15	1996-12-09	Alcon Lab Inc	Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5246948A (en)	1991-05-10	1993-09-21	Takeda Chemical Industries, Ltd.	Pyridine derivatives, their production and use
US5200400A (en)	1991-07-12	1993-04-06	New England Deaconess Hospital Corporation	Method for inhibiting allograft rejection using photoactivatable nucleotides or nucleosides
CA2074864A1 (en)	1991-07-30	1993-01-31	Carmen Almansa	Tetralones with pharmacological activity
US5352456A (en)	1991-10-10	1994-10-04	Cygnus Therapeutic Systems	Device for administering drug transdermally which provides an initial pulse of drug
US5728536A (en)	1993-07-29	1998-03-17	St. Jude Children's Research Hospital	Jak kinases and regulation of Cytokine signal transduction
DE4141746A1 (de)	1991-12-13	1993-06-17	Schering Ag	20-methyl-substituierte vitamin d-derivate
CA2123809A1 (en)	1991-12-18	1993-06-24	Debra L. Wilfong	Multilayered barrier structures
ATE132381T1 (de)	1992-01-29	1996-01-15	Voelkl Franz Ski	Ballspielschläger, insbesondere tennisschläger
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
US5194431A (en)	1992-07-08	1993-03-16	Wisconsin Alumni Research Foundation	24-cyclopropane vitamin D derivatives
DE69329136T2 (de) *	1992-10-14	2001-06-07	Mitsubishi Chemical Corp., Tokio/Tokyo	Verfahren zur Herstellung einer thermoplastischen Harzzusammensetzung
US5335501A (en)	1992-11-16	1994-08-09	General Electric Company	Flow spreading diffuser
TW287160B (pt)	1992-12-10	1996-10-01	Hoffmann La Roche
DE4308034A1 (de) *	1993-03-13	1994-09-15	Cassella Ag	Neue Heterocyclen, ihre Herstellung und ihre Verwendung
CA2174080A1 (en)	1993-10-12	1995-04-20	Paul Edward Aldrich	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
IL112290A (en)	1994-01-12	1999-01-26	Novartis Ag	Transformed aryl and the troiryl pyrimidines and herbicides containing them
US5585381A (en)	1994-06-01	1996-12-17	Kureha Chemical Industry Co., Ltd.	Pyrimidine derivatives and pharmaceutical composition
IL114193A (en)	1994-06-20	2000-02-29	Teva Pharma	Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es)	1994-08-08	1997-08-01	Cusi Lab	Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5733932A (en)	1995-01-06	1998-03-31	The Picower Institute For Medical Research	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US6242434B1 (en)	1997-08-08	2001-06-05	Bone Care International, Inc.	24-hydroxyvitamin D, analogs and uses thereof
US6316635B1 (en)	1995-06-07	2001-11-13	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
US5700904A (en)	1995-06-07	1997-12-23	Eli Lilly And Company	Preparation of an acylated protein powder
GB9516121D0 (en)	1995-08-05	1995-10-04	Pfizer Ltd	Organometallic addition to ketones
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
IT1283911B1 (it)	1996-02-05	1998-05-07	Farmigea Spa	Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
JP4058129B2 (ja)	1996-03-18	2008-03-05	株式会社資生堂	ピリジン誘導体及び抗潰瘍剤、抗菌剤
TW440563B (en)	1996-05-23	2001-06-16	Hoffmann La Roche	Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US6696448B2 (en)	1996-06-05	2004-02-24	Sugen, Inc.	3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
GB9619284D0 (en)	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
US6004985A (en)	1996-10-09	1999-12-21	Berlex Laboratories, Inc.	Thio acid derived monocylic N-heterocyclics as anticoagulants
US5800807A (en)	1997-01-29	1998-09-01	Bausch & Lomb Incorporated	Ophthalmic compositions including glycerin and propylene glycol
KR20000070751A (ko)	1997-02-05	2000-11-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
US6316429B1 (en)	1997-05-07	2001-11-13	Sugen, Inc.	Bicyclic protein kinase inhibitors
US6486185B1 (en)	1997-05-07	2002-11-26	Sugen, Inc.	3-heteroarylidene-2-indolinone protein kinase inhibitors
US6987113B2 (en)	1997-06-11	2006-01-17	Sugen, Inc.	Tyrosine kinase inhibitors
SE9702401D0 (sv)	1997-06-19	1997-06-19	Astra Ab	Pharmaceutical use
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
US6133305A (en)	1997-09-26	2000-10-17	Sugen, Inc.	3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6093820A (en)	1997-10-02	2000-07-25	Taro Pharmaceutical Industries Ltd.	Method and reagents for N-alkylating ureides
US6022884A (en)	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
GB9723859D0 (en)	1997-11-12	1998-01-07	Zeneca Ltd	Compound,composition and use
DE19750701A1 (de)	1997-11-15	1999-05-20	Dystar Textilfarben Gmbh & Co	Verfahren zur Umsetzung von fluorsubstituierten Heterocyclen mit Aminen in Gegenwart von Phasentransfer-Katalysatoren
AU1507199A (en) *	1997-12-15	1999-07-05	Yamanouchi Pharmaceutical Co., Ltd.	Novel pyrimidine-5-carboxamide derivatives
US5985856A (en)	1997-12-31	1999-11-16	University Of Kansas	Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
DK1054874T3 (da)	1998-02-13	2002-12-30	Upjohn Co	Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
JP2002503662A (ja)	1998-02-17	2002-02-05	テュラリクインコーポレイテッド	抗ウイルス性ピリミジン誘導体
EP1064289A1 (en)	1998-03-18	2001-01-03	Ariad Pharmaceuticals, Inc.	Heterocyclic signal transduction inhibitors, compositions containing them
AU751573C (en) *	1998-03-27	2003-10-09	Janssen Pharmaceutica N.V.	HIV inhibiting pyrimidine derivatives
ES2361146T3 (es)	1998-03-27	2011-06-14	Janssen Pharmaceutica Nv	Derivados de la piramidina inhibitatoria de vih.
GB9806739D0 (en)	1998-03-28	1998-05-27	Univ Newcastle Ventures Ltd	Cyclin dependent kinase inhibitors
WO1999050249A2 (en)	1998-04-01	1999-10-07	Du Pont Pharmaceuticals Company	Pyrimidines and triazines as integrin antagonists
US6261547B1 (en)	1998-04-07	2001-07-17	Alcon Manufacturing, Ltd.	Gelling ophthalmic compositions containing xanthan gum
ES2272061T5 (es)	1998-04-15	2012-02-24	Merck Serono Biodevelopment	Secuencia genómica de la proteína activadora de 5-lipoxigenasa (flap), marcadores polimórficos de la misma y métodos para la detección de asma.
NZ526958A (en)	1998-05-22	2004-12-24	Smithkline Beecham Corp	Novel 2-alkyl substituted imidazole compounds
US6197934B1 (en)	1998-05-22	2001-03-06	Collagenesis, Inc.	Compound delivery using rapidly dissolving collagen film
EP1091739A1 (en)	1998-06-30	2001-04-18	Parker Hughes Institute	Method for inhibiting c-jun expression using jak-3 inhibitors
EP1105378B1 (en)	1998-08-21	2005-03-30	Parker Hughes Institute	Quinazoline derivatives
DE69933680T2 (de)	1998-08-29	2007-08-23	Astrazeneca Ab	Pyrimidine verbindungen
WO2000015214A1 (en) *	1998-09-11	2000-03-23	Ilexus Pty Limited	Fc RECEPTOR MODULATORS AND USES THEREOF
DE19851421A1 (de)	1998-11-07	2000-05-11	Boehringer Ingelheim Pharma	Neue Pyrimidine, deren Herstellung und Verwendung
JP3635238B2 (ja) *	1998-11-10	2005-04-06	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｉｖの複製を阻害するピリミジン類
WO2000027802A1 (en)	1998-11-12	2000-05-18	Ariad Pharmaceuticals, Inc.	Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
US6127376A (en)	1998-12-04	2000-10-03	Berlex Laboratories, Inc.	Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
FR2788977B1 (fr)	1999-02-02	2002-04-19	Seb Sa	Revetement de matieres thermoplastiques pour epilation
US6841567B1 (en)	1999-02-12	2005-01-11	Cephalon, Inc.	Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6673908B1 (en)	1999-02-22	2004-01-06	Nuvelo, Inc.	Tumor necrosis factor receptor 2
US6624171B1 (en)	1999-03-04	2003-09-23	Smithkline Beecham Corporation	Substituted aza-oxindole derivatives
GB9904995D0 (en)	1999-03-04	1999-04-28	Glaxo Group Ltd	Substituted aza-oxindole derivatives
US6080747A (en)	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
SE9901079D0 (sv)	1999-03-23	1999-03-23	Astra Ab	Novel compounds
EE200100502A (et) *	1999-03-26	2002-12-16	Astrazeneca Ab	Ühendid
WO2000059893A1 (en)	1999-04-06	2000-10-12	Krenitsky Pharmaceuticals Inc.	Neurotrophic thio substituted pyrimidines
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
DE19917785A1 (de)	1999-04-20	2000-10-26	Bayer Ag	2,4-Diamino-pyrimidin-Derivate
AU5108000A (en)	1999-06-10	2001-01-02	Yamanouchi Pharmaceutical Co., Ltd.	Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
TWI262914B (en)	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
GB9918035D0 (en)	1999-07-30	1999-09-29	Novartis Ag	Organic compounds
DE19945982A1 (de) *	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
DE60025837T2 (de)	1999-09-24	2006-11-02	Janssen Pharmaceutica N.V.	Antivirale feste dispersionen
OA12050A (en)	1999-09-30	2006-05-02	Neurogen Corp	Certain alkylene diamine-substituted heterocycles.
KR100317935B1 (ko)	1999-10-20	2001-12-22	유승필	대사성 골질환 치료용 약제조성물 및 이의 제조방법
AU1026901A (en)	1999-10-29	2001-05-08	Syngenta Participations Ag	Novel herbicides
WO2001045641A2 (en)	1999-11-30	2001-06-28	Parker Hughes Institute	Inhibitors of thrombin induced platelet aggregation
EA006227B1 (ru)	1999-12-10	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
CA2395520A1 (en)	1999-12-21	2001-06-28	Sugen, Inc.	4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
ATE449764T1 (de)	1999-12-28	2009-12-15	Pharmacopeia Inc	Cytokine, insbesondere tnf-alpha, hemmer
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
US6362172B2 (en)	2000-01-20	2002-03-26	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
ATE369844T1 (de)	2000-01-24	2007-09-15	Genzyme Corp	Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
IL145757A (en)	2000-02-05	2007-12-03	Vertex Pharma	History of pyrazole and pharmaceutical preparations containing them
WO2001056993A2 (en)	2000-02-05	2001-08-09	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of erk
HUP0301117A3 (en) *	2000-02-17	2004-01-28	Amgen Inc Thousand Oaks	Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004886D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
US6608048B2 (en)	2000-03-28	2003-08-19	Wyeth Holdings	Tricyclic protein kinase inhibitors
AR028261A1 (es)	2000-03-28	2003-04-30	Wyeth Corp	Inhibidores triciclicos de la proteina quinasa
US7034019B2 (en) *	2000-05-08	2006-04-25	Janssen Pharmaceutica N.V.	Prodrugs of HIV replication inhibiting pyrimidines
US7276510B2 (en)	2000-05-08	2007-10-02	Janssen Pharmaceutica, Inc.	HIV replication inhibitors
EA006153B1 (ru)	2000-06-26	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
US20050009876A1 (en)	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
EP1311637B8 (en)	2000-08-18	2006-06-28	3M Innovative Properties Company	Fluoroalkyl (meth)acrylate copolymer coating compositions
ES2266258T3 (es)	2000-09-15	2007-03-01	Vertex Pharmaceuticals Incorporated	Compuestos de pirazol utiles como inhibidores de proteina cinasas.
AU2001296542B2 (en)	2000-10-02	2007-10-25	Emory University	Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6448401B1 (en)	2000-11-20	2002-09-10	Bristol-Myers Squibb Company	Process for water soluble azole compounds
WO2002043735A1 (en)	2000-11-29	2002-06-06	Parker Hughes Institute	Inhibitors of thrombin induced platelet aggregation
US20020137755A1 (en)	2000-12-04	2002-09-26	Bilodeau Mark T.	Tyrosine kinase inhibitors
US20020115173A1 (en)	2000-12-11	2002-08-22	Children's Medical Center Corporation	Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
AR035721A1 (es)	2000-12-20	2004-07-07	Sugen Inc	Indolinonas 4-aril sustituidas; sus composiciones farmaceuticas y metodo para modular la actividad catalitica de una proteina quinasa
EP1345925B1 (en)	2000-12-21	2006-05-17	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
ES2556946T3 (es)	2000-12-21	2016-01-21	Novartis Ag	Pirimidinaminas como moduladores de la angiogénesis
AUPR279101A0 (en)	2001-01-30	2001-02-22	Cytopia Pty Ltd	Protein kinase signalling
EP1363702A4 (en)	2001-01-30	2007-08-22	Cytopia Pty Ltd	PROCESS FOR INHIBITING KINASES
WO2002064096A2 (en)	2001-02-16	2002-08-22	Tularik Inc.	Methods of using pyrimidine-based antiviral agents
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
BR0207096A (pt)	2001-02-20	2004-01-20	Astrazeneca Ab	Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
GB2373186A (en) *	2001-02-23	2002-09-18	Astrazeneca Ab	Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
WO2002068409A1 (en)	2001-02-23	2002-09-06	Merck & Co., Inc.	N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US20030165873A1 (en)	2001-03-02	2003-09-04	Come Jon H.	Three hybrid assay system
AU2002312933B2 (en)	2001-05-29	2007-12-06	Schering Ag	CDK inhibiting pyrimidines, production thereof and their use as medicaments
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
MXPA03010961A (es)	2001-05-31	2004-02-27	Vertex Pharma	Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
CA2446756C (en)	2001-06-01	2011-03-08	Vertex Pharmaceuticals Incorporated	Thiazole compounds useful as inhibitors of protein kinase
DE60232510D1 (de)	2001-06-15	2009-07-16	Vertex Pharma	5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
WO2002102313A2 (en)	2001-06-19	2002-12-27	Bristol-Myers Squibb Company	Pyrimidine inhibitors of phosphodiesterase (pde) 7
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
US6878697B2 (en)	2001-06-21	2005-04-12	Ariad Pharmaceuticals, Inc.	Phenylamino-pyrimidines and uses thereof
GB0115393D0 (en)	2001-06-23	2001-08-15	Aventis Pharma Ltd	Chemical compounds
AP2003002929A0 (en)	2001-06-23	2003-12-31	Aventis Pharma Inc	Pyrrolopyrimidines as protein kinase inhibitors
CA2451128A1 (en) *	2001-06-26	2003-01-09	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of tnf-alpha expression
CZ294535B6 (cs)	2001-08-02	2005-01-12	Ústav Experimentální Botaniky Avčr	Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) *	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en)	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
US6433018B1 (en)	2001-08-31	2002-08-13	The Research Foundation Of State University Of New York	Method for reducing hypertrophy and ischemia
US6952284B2 (en) *	2001-08-31	2005-10-04	International Business Machines Corporation	Manually operated digital printing device
US7070996B2 (en)	2001-08-31	2006-07-04	Rigel Pharmaceuticals, Inc.	Production of cultured human mast cells and basophils for high throughput small molecule drug discovery
AU2002334355A1 (en)	2001-09-06	2003-03-18	Prochon Biotech Ltd.	Protein tyrosine kinase inhibitors
EP1436259A1 (en)	2001-09-10	2004-07-14	Congxin Liang	3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
WO2003030909A1 (en) *	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026664A1 (en)	2001-09-26	2003-04-03	Bayer Corporation	2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en)	2001-09-28	2003-05-15	Bayer Pharmaceuticals Corporation	Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
EP1453516A2 (de)	2001-10-17	2004-09-08	Boehringer Ingelheim Pharma GmbH & Co.KG	5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
DK1438053T3 (da)	2001-10-17	2008-12-08	Boehringer Ingelheim Pharma	Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
US6897208B2 (en)	2001-10-26	2005-05-24	Aventis Pharmaceuticals Inc.	Benzimidazoles
MXPA04005027A (es)	2001-11-28	2004-08-11	Btg Int Ltd	Preventivos o remedios para la enfermedad de alzheimer, o inhibidores de la formacion de fibrillas de proteina amiloide, que incluyen un compuesto heteroarilo que contiene nitrogeno.
PY0228255A (es)	2001-12-06	2004-06-01	Pfizer Prod Inc	Compuestos cristalinos novedosos
SE0104140D0 (sv)	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
WO2003055489A1 (en)	2001-12-21	2003-07-10	Bayer Pharmaceuticals Corporation	2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
US6924290B2 (en)	2002-01-23	2005-08-02	Bayer Pharmaceuticals Corporation	Rho-kinase inhibitors
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
FR2835522B1 (fr)	2002-02-06	2006-04-07	Robert Vachy	Preparation pour composes sensibles a l'oxydation et son procede de fabrication
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
WO2003066601A1 (en)	2002-02-08	2003-08-14	Smithkline Beecham Corporation	Pyrimidine compounds
US7153245B2 (en) *	2002-02-14	2006-12-26	Kellion Corporation	Golf exerciser
US7338959B2 (en)	2002-03-01	2008-03-04	Smithkline Beecham Corporation	Diamino-pyrimidines and their use as angiogenesis inhibitors
EP1483260A1 (de)	2002-03-11	2004-12-08	Schering Aktiengesellschaft	Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
US7288547B2 (en)	2002-03-11	2007-10-30	Schering Ag	CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
WO2003080047A1 (en)	2002-03-20	2003-10-02	Bristol-Myers Squibb Company	Phosphate prodrugs of fluorooxindoles
WO2004039359A2 (en)	2002-05-06	2004-05-13	Bayer Pharmaceuticals Corporation	Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
AU2003231231A1 (en)	2002-05-06	2003-11-11	Bayer Pharmaceuticals Corporation	Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AR039540A1 (es)	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
AU2003231880A1 (en)	2002-05-30	2003-12-19	Vertex Pharmaceuticals Incorporated	Inhibitors of jak and cdk2 protein kinases
US20050222186A1 (en)	2002-06-14	2005-10-06	Altana Pharma Ag	Substituted diaminopyrimidines
CN1688553A (zh)	2002-06-17	2005-10-26	史密丝克莱恩比彻姆公司	化学方法
EP1518855B1 (en)	2002-06-28	2011-10-26	Astellas Pharma Inc.	Diaminopyrimidinecarboxa mide derivative
BR0313059B8 (pt)	2002-07-29	2021-07-27	Rigel Pharmaceuticals	composto, e, composição farmacêutica
WO2004014384A2 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
CA2495386C (en)	2002-08-14	2011-06-21	Vertex Pharmaceuticals Incorporated	Protein kinase inhibitors and uses thereof
EP2172460A1 (en)	2002-11-01	2010-04-07	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of JAK and other protein kinases
US7259161B2 (en)	2002-11-04	2007-08-21	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of JAK and other protein kinases
US7348335B2 (en)	2002-11-05	2008-03-25	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of JAK and other protein kinases
GB0226582D0 (en)	2002-11-14	2002-12-18	Cyclacel Ltd	Anti-viral compounds
GB0226583D0 (en)	2002-11-14	2002-12-18	Cyclacel Ltd	Compounds
AR042052A1 (es)	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
CN101353321A (zh)	2002-11-21	2009-01-28	辉瑞产品公司	3-氨基-哌啶衍生物及其制备方法
AU2003276591A1 (en)	2002-11-26	2004-06-18	Pfizer Products Inc.	Method of treatment of transplant rejection
KR20050084027A (ko)	2002-11-28	2005-08-26	쉐링 악티엔게젤샤프트	Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004052359A1 (en)	2002-12-09	2004-06-24	The Board Of Regents Of The University Of Texas System	Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
WO2004054617A1 (ja)	2002-12-13	2004-07-01	Kyowa Hakko Kogyo Co., Ltd.	中枢疾患の予防および／または治療剤
ATE425160T1 (de)	2002-12-18	2009-03-15	Vertex Pharma	Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
DE602004022633D1 (de)	2003-01-30	2009-10-01	Boehringer Ingelheim Pharma	2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
PL227577B1 (pl)	2003-02-07	2017-12-29	Janssen Pharmaceutica Nv	Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
CL2004000303A1 (es)	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
DE602004021472D1 (en)	2003-02-20	2009-07-23	Smithkline Beecham Corp	Pyrimiidinverbindungen
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
WO2004092154A1 (en)	2003-04-03	2004-10-28	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
MXPA05011352A (es)	2003-04-23	2005-11-28	Glaxo Group Ltd	Derivados de piperazina y su uso para el tratamiento de enfermedades neurologicas y psiquiatricas.
DE602004008762T2 (de)	2003-04-30	2008-06-12	The Institutes for Pharmaceutical Discovery, LLC, Branford	Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
GB0311274D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
GB0311276D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
WO2005007621A2 (en)	2003-05-30	2005-01-27	Rigel Pharmaceuticals, Inc.	Ubiquitin ligase inhibitors
AU2004257260A1 (en)	2003-07-10	2005-01-27	Neurogen Corporation	Substituted heterocyclic diarylamine analogues
JP2007526894A (ja)	2003-07-16	2007-09-20	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	グリコーゲンシンターゼキナーゼ３インヒビターとしてのトリアゾロピリミジン誘導体
ATE370142T1 (de)	2003-07-16	2007-09-15	Janssen Pharmaceutica Nv	Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
US20070161637A1 (en)	2003-07-22	2007-07-12	Neurogen Corporation	Substituted pyridin-2-ylamine analogues
US7442698B2 (en)	2003-07-24	2008-10-28	Amgen Inc.	Substituted heterocyclic compounds and methods of use
WO2005009957A1 (en)	2003-07-24	2005-02-03	Merck & Co., Inc.	Tyrosine kinase inhibitors
CN102358738A (zh)	2003-07-30	2012-02-22	里格尔药品股份有限公司	2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
EP1648875A1 (en)	2003-07-30	2006-04-26	Cyclacel Limited	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
AU2004263148B2 (en)	2003-08-06	2008-08-21	Vertex Pharmaceuticals, Incorporated	Aminotriazole compounds useful as inhibitors of protein kinases
EP1663242B1 (en)	2003-08-07	2011-04-27	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
BRPI0413469A (pt)	2003-08-14	2006-10-17	Pfizer	derivados de piperazina para o tratamento de infecções por hiv
TWI378923B (en)	2003-08-15	2012-12-11	Novartis Ag	Pyrimidine derivatives
TWI339206B (en)	2003-09-04	2011-03-21	Vertex Pharma	Compositions useful as inhibitors of protein kinases
WO2005028467A1 (en)	2003-09-15	2005-03-31	Anadys Pharmaceuticals, Inc.	Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
GB0321710D0 (en)	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
BRPI0414544A (pt)	2003-09-18	2006-11-07	Novartis Ag	2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos
WO2005027848A2 (en)	2003-09-19	2005-03-31	Barnes-Jewish Hospital	Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
AP2006003517A0 (en)	2003-09-25	2006-02-28	Janssen Pharmaceutica Nv	Hiv replication purine derivatives.
MXPA06003749A (es)	2003-10-03	2006-06-14	Pfizer	Derivados de tropano.
DE10349423A1 (de)	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7235161B2 (en) *	2003-11-19	2007-06-26	Alcoa Inc.	Stable anodes including iron oxide and use of such anodes in metal production cells
TW200529849A (en)	2003-11-28	2005-09-16	Novartis Ag	Diaryl urea derivatives in the treatment of protein kinase dependent diseases
MY141255A (en)	2003-12-11	2010-03-31	Memory Pharm Corp	Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2007514775A (ja)	2003-12-19	2007-06-07	ライジェルファーマシューティカルズ，インコーポレイテッド	１−（２，４−ピリミジンジアミノ）−２−シクロペンタンカルボキサイミド合成中間体の立体異性体および立体異性体混合物
US20080207613A1 (en)	2004-01-12	2008-08-28	Cytopia Research Pty Ltd	Selective Kinase Inhibitors
GB0402653D0 (en)	2004-02-06	2004-03-10	Cyclacel Ltd	Compounds
CA2553785C (en)	2004-02-14	2011-02-08	Irm Llc	Compounds and compositions as protein kinase inhibitors
US7745625B2 (en)	2004-03-15	2010-06-29	Bristol-Myers Squibb Company	Prodrugs of piperazine and substituted piperidine antiviral agents
WO2005107760A1 (en)	2004-04-30	2005-11-17	Irm Llc	Compounds and compositions as inducers of keratinocyte differentiation
US7754714B2 (en)	2004-05-18	2010-07-13	Rigel Pharmaceuticals, Inc.	Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB0419161D0 (en)	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
US20060047135A1 (en)	2004-08-30	2006-03-02	Chadwick Scott T	Process for preparing chloromethyl di-tert-butylphosphate
WO2006028833A1 (en)	2004-09-01	2006-03-16	Rigel Pharmaceuticals, Inc.	Synthesis of 2,4-pyrimidinediamine compounds
EP1794134A1 (de)	2004-09-29	2007-06-13	Bayer Schering Pharma Aktiengesellschaft	Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
US7585883B2 (en)	2004-10-29	2009-09-08	Rigel Pharmaceuticals, Inc.	Substituted pyridines and their uses
JP5095409B2 (ja)	2004-11-24	2012-12-12	ライジェルファーマシューティカルズ，インコーポレイテッド	スピロ２，４−ピリミジンジアミン化合物およびその使用
US7442716B2 (en)	2004-12-17	2008-10-28	Merck Frosst Canada Ltd.	2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
CA2590110C (en)	2004-12-30	2014-06-03	Exelixis, Inc.	Kinase modulators and method of use
JP4801096B2 (ja)	2005-01-19	2011-10-26	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
US20060270694A1 (en)	2005-05-03	2006-11-30	Rigel Pharmaceuticals, Inc.	JAK kinase inhibitors and their uses
US20060251285A1 (en)	2005-05-05	2006-11-09	Mrs. Yen-Chen Chan	[surge-proof damper]
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP1904457B1 (en) *	2005-06-08	2017-09-06	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CA2607901C (en)	2005-06-13	2016-08-16	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
NZ564872A (en)	2005-07-11	2010-01-29	Sanofi Aventis	Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
JP5227795B2 (ja)	2005-07-28	2013-07-03	インターベツト・インターナシヨナル・ベー・ベー	抗寄生虫活性を有する新規ベンゾイミダゾール（チオ）カルバメートおよびその合成
CN101282979B (zh)	2005-09-13	2011-09-21	卫材R&D管理有限公司	稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
WO2007053844A2 (en)	2005-10-31	2007-05-10	Rigel Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory disorders
US7528143B2 (en)	2005-11-01	2009-05-05	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US7713987B2 (en)	2005-12-06	2010-05-11	Rigel Pharmaceuticals, Inc.	Pyrimidine-2,4-diamines and their uses
WO2007076427A2 (en)	2005-12-21	2007-07-05	Konarka Technologies, Inc.	Tandem photovoltaic cells
US7962290B1 (en) *	2006-01-09	2011-06-14	Rigel Pharmaceuticals, Inc.	Identification of pharmacophores from co-crystals of spleen tyrosine kinase (SYK) and SYK ligands
TW200736232A (en)	2006-01-26	2007-10-01	Astrazeneca Ab	Pyrimidine derivatives
WO2007085540A1 (en)	2006-01-27	2007-08-02	Glaxo Group Limited	1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
JP4653842B2 (ja)	2006-02-17	2011-03-16	ライジェルファーマシューティカルズ，インコーポレイテッド	自己免疫疾患を治療または予防するための２，４−ピリミジンジアミン化合物
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
WO2007124589A1 (en)	2006-05-02	2007-11-08	Merck Frosst Canada Ltd.	Methods for treating or preventing neoplasias
US7776855B2 (en)	2006-07-27	2010-08-17	Janssen Pharmaceutica N.V.	Antimicrobial oxazolidinone prodrugs
ATE497496T1 (de)	2006-10-19	2011-02-15	Rigel Pharmaceuticals Inc	2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
US7947698B2 (en) *	2007-03-23	2011-05-24	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
US7834024B2 (en) *	2007-03-26	2010-11-16	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
CN101903357A (zh)	2007-07-17	2010-12-01	里格尔药品股份有限公司	作为pkc抑制剂的环状胺取代的嘧啶二胺
HRP20181286T1 (hr) *	2011-03-10	2018-10-05	Rigel Pharmaceuticals, Inc.	2,4 supstituirani pirimidindiamini za uporabu kod diskoidnog lupusa

2003
- 2003-01-30 TW TW92102315A patent/TWI329105B/zh not_active IP Right Cessation
- 2003-01-31 EP EP20100011119 patent/EP2281563B1/en not_active Expired - Lifetime
- 2003-01-31 DK DK10011119T patent/DK2281563T3/da active
- 2003-01-31 PL PL373530A patent/PL214988B1/pl unknown
- 2003-01-31 AT AT03707654T patent/ATE524184T1/de active
- 2003-01-31 ES ES10011119T patent/ES2440283T3/es not_active Expired - Lifetime
- 2003-01-31 RS RS20120098A patent/RS54105B1/sr unknown
- 2003-01-31 HR HRP20040684AA patent/HRP20040684B1/hr not_active IP Right Cessation
- 2003-01-31 BR BRPI0307355A patent/BRPI0307355C1/pt not_active IP Right Cessation
- 2003-01-31 SI SI200332084T patent/SI1471915T1/sl unknown
- 2003-01-31 RS YUP67404 patent/RS53367B/sr unknown
- 2003-01-31 CN CN201110056352.5A patent/CN102174024B/zh not_active Expired - Lifetime
- 2003-01-31 ES ES03707654T patent/ES2373646T3/es not_active Expired - Lifetime
- 2003-01-31 JP JP2003563490A patent/JP4658477B2/ja not_active Expired - Lifetime
- 2003-01-31 CN CN038031809A patent/CN1625400B/zh not_active Expired - Lifetime
- 2003-01-31 AU AU2003208931A patent/AU2003208931C1/en not_active Expired
- 2003-01-31 DK DK03707654T patent/DK1471915T3/da active
- 2003-01-31 PT PT03707654T patent/PT1471915E/pt unknown
- 2003-01-31 WO PCT/US2003/003022 patent/WO2003063794A2/en not_active Ceased
- 2003-01-31 SI SI200332327T patent/SI2281563T1/sl unknown
- 2003-01-31 KR KR1020047011935A patent/KR101037856B1/ko not_active Expired - Fee Related
- 2003-01-31 CA CA 2474277 patent/CA2474277C/en not_active Expired - Lifetime
- 2003-01-31 MX MXPA04007386A patent/MXPA04007386A/es active IP Right Grant
- 2003-01-31 EP EP20030707654 patent/EP1471915B1/en not_active Expired - Lifetime
- 2003-01-31 US US10/355,543 patent/US7557210B2/en not_active Expired - Lifetime
- 2003-01-31 NZ NZ534361A patent/NZ534361A/en not_active IP Right Cessation
- 2003-01-31 PT PT10011119T patent/PT2281563E/pt unknown
- 2003-01-31 SG SG200605315-1A patent/SG167664A1/en unknown
2004
- 2004-06-01 US US10/858,343 patent/US7060827B2/en not_active Expired - Lifetime
- 2004-07-30 MX MX2011005027A patent/MX341239B/es unknown
- 2004-08-03 US US10/911,684 patent/US7589200B2/en not_active Expired - Lifetime
- 2004-08-31 NO NO20043632A patent/NO328071B1/no not_active IP Right Cessation
2005
- 2005-06-08 US US11/149,105 patent/US7329672B2/en not_active Expired - Lifetime
- 2005-06-08 US US11/148,746 patent/US7329671B2/en not_active Expired - Lifetime
- 2005-06-08 US US11/149,418 patent/US7332484B2/en not_active Expired - Lifetime
- 2005-12-08 US US11/299,207 patent/US7435814B2/en not_active Expired - Lifetime
2006
- 2006-10-05 US US11/539,029 patent/US7642351B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/539,013 patent/US7906644B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/539,041 patent/US20070293522A1/en not_active Abandoned
- 2006-10-05 US US11/539,054 patent/US7485724B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/539,049 patent/US7820819B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/539,018 patent/US7498435B2/en not_active Expired - Lifetime
2007
- 2007-07-24 US US11/782,581 patent/US7550460B2/en not_active Expired - Lifetime
2008
- 2008-08-27 US US12/199,705 patent/US7655797B2/en not_active Expired - Lifetime
- 2008-11-10 US US12/268,235 patent/US7803939B2/en not_active Expired - Lifetime
- 2008-11-18 US US12/273,357 patent/US8334296B2/en not_active Expired - Fee Related
- 2008-12-03 AU AU2008252053A patent/AU2008252053A1/en not_active Abandoned
2009
- 2009-01-30 US US12/363,537 patent/US8188276B2/en not_active Expired - Fee Related
2010
- 2010-04-16 US US12/762,178 patent/US8148525B2/en not_active Expired - Fee Related
- 2010-07-26 JP JP2010166848A patent/JP5357116B2/ja not_active Expired - Lifetime
2011
- 2011-01-21 US US13/011,407 patent/US10682350B2/en not_active Expired - Lifetime
- 2011-11-03 US US13/288,813 patent/US8410266B2/en not_active Expired - Fee Related
- 2011-12-14 CY CY20111101247T patent/CY1112516T1/el unknown
2012
- 2012-08-09 IL IL221381A patent/IL221381A/en active IP Right Grant
2013
- 2013-02-05 US US13/759,835 patent/US8853397B2/en not_active Expired - Lifetime
- 2013-06-04 US US13/909,830 patent/US8748597B2/en not_active Expired - Lifetime
- 2013-08-07 US US13/961,780 patent/US8822685B2/en not_active Expired - Lifetime
- 2013-09-26 US US14/038,521 patent/US8835430B2/en not_active Expired - Lifetime
2014
- 2014-06-19 US US14/309,530 patent/US9133133B2/en not_active Expired - Fee Related
- 2014-07-16 US US14/333,163 patent/US9040550B2/en not_active Expired - Lifetime
- 2014-09-12 US US14/485,045 patent/US9416112B2/en not_active Expired - Fee Related
2015
- 2015-01-12 US US14/594,862 patent/US9018204B1/en not_active Expired - Fee Related
- 2015-02-19 US US14/626,471 patent/US9162989B2/en not_active Expired - Fee Related
- 2015-03-30 US US14/672,679 patent/US9346765B2/en not_active Expired - Fee Related
- 2015-07-29 US US14/812,829 patent/US9540334B2/en not_active Expired - Fee Related
- 2015-09-18 US US14/858,661 patent/US9586908B2/en not_active Expired - Fee Related
- 2015-09-22 US US14/861,739 patent/US9499493B2/en not_active Expired - Fee Related
2016
- 2016-07-08 US US15/205,725 patent/US9913842B2/en not_active Expired - Fee Related
- 2016-12-01 US US15/366,931 patent/US10369148B2/en not_active Expired - Fee Related
2017
- 2017-02-27 US US15/443,145 patent/US10314840B2/en not_active Expired - Fee Related
2019
- 2019-05-03 US US16/402,912 patent/US10828301B2/en not_active Expired - Fee Related
- 2019-06-19 US US16/445,597 patent/US11007193B2/en not_active Expired - Fee Related
- 2019-11-21 US US16/691,352 patent/US10709703B2/en not_active Expired - Fee Related
2021
- 2021-05-03 US US17/246,980 patent/US20210267971A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150158823A1 (en)	2015-06-11
KR101037856B1 (ko)	2011-06-01
US20060058292A1 (en)	2006-03-16
MX341239B (es)	2016-08-12
US9540334B2 (en)	2017-01-10
US7329672B2 (en)	2008-02-12
YU67404A (sh)	2006-08-17
CN102174024B (zh)	2015-02-11
BRPI0307355B8 (pt)	2019-08-06
US8835430B2 (en)	2014-09-16
US10709703B2 (en)	2020-07-14
US20160009661A1 (en)	2016-01-14
JP2010285441A (ja)	2010-12-24
SG167664A1 (en)	2011-01-28
US20140303154A1 (en)	2014-10-09
US8188276B2 (en)	2012-05-29
US20150329532A1 (en)	2015-11-19
US20190255047A1 (en)	2019-08-22
US20120045454A1 (en)	2012-02-23
US20140330007A1 (en)	2014-11-06
US20190358228A1 (en)	2019-11-28
US7803939B2 (en)	2010-09-28
US20170246167A1 (en)	2017-08-31
US8148525B2 (en)	2012-04-03
US20070293523A1 (en)	2007-12-20
BRPI0307355B1 (pt)	2018-11-13
RS54105B1 (sr)	2015-10-30
US7550460B2 (en)	2009-06-23
US7060827B2 (en)	2006-06-13
US20060035916A1 (en)	2006-02-16
CN102174024A (zh)	2011-09-07
US7589200B2 (en)	2009-09-15
RS53367B (sr)	2014-10-31
US9018204B1 (en)	2015-04-28
WO2003063794A3 (en)	2003-12-04
US7485724B2 (en)	2009-02-03
US20090082567A1 (en)	2009-03-26
US20060025410A1 (en)	2006-02-02
US9040550B2 (en)	2015-05-26
NZ534361A (en)	2008-04-30
EP1471915A2 (en)	2004-11-03
ES2440283T3 (es)	2014-01-28
HRP20040684B1 (hr)	2014-07-04
US10369148B2 (en)	2019-08-06
US9913842B2 (en)	2018-03-13
US20090171085A1 (en)	2009-07-02
US20070225321A1 (en)	2007-09-27
CA2474277C (en)	2013-09-24
US8853397B2 (en)	2014-10-07
US7820819B2 (en)	2010-10-26
US9586908B2 (en)	2017-03-07
RS20120098A1 (sr)	2012-08-31
ATE524184T1 (de)	2011-09-15
US20130317216A1 (en)	2013-11-28
EP1471915B1 (en)	2011-09-14
NO20043632L (no)	2004-10-26
PL373530A1 (en)	2005-09-05
MXPA04007386A (es)	2006-04-27
CN1625400A (zh)	2005-06-08
BR0307355A (pt)	2006-04-11
BRPI0307355C1 (pt)	2021-05-25
HRP20040684A2 (hr)	2008-12-31
CN1625400B (zh)	2011-04-13
US20170081290A1 (en)	2017-03-23
US20070293520A1 (en)	2007-12-20
PT2281563E (pt)	2013-12-09
US7435814B2 (en)	2008-10-14
US10314840B2 (en)	2019-06-11
US7642351B2 (en)	2010-01-05
US7557210B2 (en)	2009-07-07
US10828301B2 (en)	2020-11-10
US9346765B2 (en)	2016-05-24
SI2281563T1 (sl)	2014-02-28
TW200307547A (en)	2003-12-16
US20140031350A1 (en)	2014-01-30
EP2281563B1 (en)	2013-09-18
PT1471915E (pt)	2011-12-26
US9162989B2 (en)	2015-10-20
US11007193B2 (en)	2021-05-18
CY1112516T1 (el)	2015-12-09
US20070293524A1 (en)	2007-12-20
US7332484B2 (en)	2008-02-19
US20150266828A1 (en)	2015-09-24
JP4658477B2 (ja)	2011-03-23
US20060135543A1 (en)	2006-06-22
ES2373646T3 (es)	2012-02-07
US20170151239A1 (en)	2017-06-01
US20090171086A1 (en)	2009-07-02
US20210267971A1 (en)	2021-09-02
PL214988B1 (pl)	2013-10-31
US20050038243A1 (en)	2005-02-17
US9499493B2 (en)	2016-11-22
US20050209230A1 (en)	2005-09-22
US8748597B2 (en)	2014-06-10
HK1154216A1 (en)	2012-04-13
US7906644B2 (en)	2011-03-15
US20040029902A1 (en)	2004-02-12
US20090156622A1 (en)	2009-06-18
AU2008252053A1 (en)	2009-01-08
US9133133B2 (en)	2015-09-15
KR20040101216A (ko)	2004-12-02
WO2003063794A2 (en)	2003-08-07
JP2005516046A (ja)	2005-06-02
CA2474277A1 (en)	2003-08-07
US7655797B2 (en)	2010-02-02
DK1471915T3 (da)	2012-01-09
US8410266B2 (en)	2013-04-02
EP1471915A4 (en)	2006-02-15
US20100197918A1 (en)	2010-08-05
US20150126504A1 (en)	2015-05-07
EP2281563A1 (en)	2011-02-09
SI1471915T1 (sl)	2012-03-30
US10682350B2 (en)	2020-06-16
AU2003208931B2 (en)	2008-09-04
JP5357116B2 (ja)	2013-12-04
US20200085820A1 (en)	2020-03-19
IL221381A0 (en)	2012-09-24
US20080039622A1 (en)	2008-02-14
AU2003208931C1 (en)	2009-04-02
US20130150349A1 (en)	2013-06-13
IL221381A (en)	2015-05-31
US20160009660A1 (en)	2016-01-14
US9416112B2 (en)	2016-08-16
US7498435B2 (en)	2009-03-03
US20110144330A1 (en)	2011-06-16
US20130324524A1 (en)	2013-12-05
US8822685B2 (en)	2014-09-02
HK1069538A1 (en)	2005-05-27
US20070293521A1 (en)	2007-12-20
TWI329105B (en)	2010-08-21
DK2281563T3 (da)	2014-01-13
US20150005297A1 (en)	2015-01-01
US8334296B2 (en)	2012-12-18
US7329671B2 (en)	2008-02-12
US20070293522A1 (en)	2007-12-20

Legal Events

Date	Code	Title	Description
2023-02-13	MK1K	Patent expired